CSE:$HBOR an exponential growth company in one of the
CSE:$HBOR an exponential growth company in one of the fastest growing industries, Cannabis.
Harborside Inc. (CSE:HBOR)
HBOR is a 12 year old retailer and cultivator of Cannabis operating in Northern California. The company is vertically integrated combining significant production capacity and retail shelf space with tremendous distribution outlets that utilize over 30 Retail Cannabis licenses to leverage scale and ensure supply chain stability.
HBOR currently operates 6 retail dispensaries throughout Northern California and additional stores will be opening within 2019. Sales growth has been staggering and the company has done in excess of $400 million in cumulative sales in the last 10 years. The company has a huge market share selling an amazing 3% of the total Cannabis sold in the state of California. The company is rapidly expanding along with their extremely popular branded product lines. Co-founded by Cannabis icon Steve DeAngelo the company's brands are known throughout California, the United States and internationally. Harborside is amongst the oldest and largest cannabis dispensaries in the world. Harborside was granted one of the first six medical cannabis licenses in the United States.
HBOR has recently become very serious about creating shareholder value for its loyal investor base. They recently retained Mattio Communications of New York. Mattio will be helping increase investor awareness through a customized, strategic investor relations program. Mattio was ranked the number 1 IR/PR firm in the Cannabis industry in 2019 by The Green Report. They should be able to bring a large pool of new investors to HBOR and a much larger international investor audience which should help move the price up dramatically from recent lows.
HBOR is not your typical Cannabis stock. Cannabis stocks often are not well capitalized, have no financial history, and are lacking a solid business model. HBOR's business model has been tested for more than 10 years in the retail space. The company is also a seasoned distributor and cultivator of branded Cannabis. HBOR is the real deal and one of my Cannabis favorites. Revenues are surging and further acquisitions are planned which will lead to a tremendous growth rate resulting in a huge respect on Wall Street. At today's price of 1.86 you should definitely load big. When sales news comes accompanied with a high caliber IR firm the PPS will skyrocket.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Innventure’s Market Tumult: Unraveling the Drama Talk about a mess. Innventure Inc. (NASDAQ: INV) investors are likely feeling a sting sharper than a bee that's lost its hive after a painful 55% stock crash back in August 2026. The culprit? A scuttled project involving a shadowy partner, DarkNX, and a lot of questions about who knew what and when. A Puzzling...
Continue Reading
The world of ocean energy just got a jolt from an unlikely corner. Minesto, the ocean energy whiz, and Morteza Capital, a savvy investment force entrenched in the Maldives, are shaking hands to usher tidal energy into this paradise. Tidal Waves Meet Tourism When you're talking about the Maldives, you're talking about two main things: pristine tropical getaways and a whole...
Continue Reading
Another Day, Another Lawsuit Just when you thought the financial waters were calm, there's a storm brewing for Bank of America Corp. (NYSE: BAC). They've been slapped with a securities class action lawsuit that screams all kinds of regulatory and compliance failures. You’d think with all that cash flow, BAC could afford to run a tight ship. But apparently, they decided...
Continue Reading
Spokane Forum Sparks Action for Veterans' Policies Gonzaga University turned into a powerhouse of dialogue and determination as the Wounded Warrior Project (WWP) gathered over 145 veterans, elected officials, and advocate groups to hash out critical policy priorities. We're talking high-stakes discussions with real consequences, not just some feel-good meet-up. A...
Continue Reading
The Heartbeat of Innovation in Cancer Therapy Who would've thought Tennessee would be at the forefront of a global push against lung cancer? Sure, there's Nashville's music scene, but it's the researchers at Tennessee Oncology who are grooving to a different beat—one that might just set the rhythm for advanced cancer therapies worldwide. Yeah, it's a trial, but not just...
Continue Reading
A Decade of Trust and Responsibility Here we go, folks—Medline is toasting 10 years with WRAP, and this ain't just fluffy PR spin. When two big players like these lock arms over responsible manufacturing, it's a signal worth paying attention to, and not just for the ethics alone. Production practices that prioritize transparency and worker rights have ramifications...
Continue Reading
Time for a Change The head of the World Water Council, Loïc Fauchon, didn't mince words at the 9th Cairo Water Week. He proclaimed the old methods of water management are sinking under a flood of modern challenges. Toss in climate upheavals, ballooning cities, and unpredictable diets, and you've got yourself a swirling mess that traditional strategies just can’t mop...
Continue Reading
UFP Industries Makes a Strategic Move Folks, it looks like UFP Industries (NASDAQ: UFPI) is making some solid moves down in the Gulf Coast, and they're shelling out $27 million to do it. This time, they've got their eyes on Apache Products, dba Acme Skid, a company that's been doing the heavy lifting in the pallet manufacturing space in Silsbee, Texas. Apparently, these...
Continue Reading
Dalrymple's Short Report Shakes Csquare's Core Csquare, Inc. (NYSE: CSQR) is reeling from a one-two punch: a damning short report by Dalrymple Finance and an 11.8% share tumble. The timing of this financial body blow, coinciding with Csquare's discordant cash flow claims, could mark the beginning of a long battle for investor trust. This ain't the first time the markets...
Continue Reading
Cracking the Code on TKI Sensitivity When it comes to medicine, sometimes the trickiest part is knowing which button to push—especially in the high-stakes world of metastatic renal cell carcinoma (mRCC). OncoHost just dropped a bombshell at the ESMO 2026 Congress about their new plasma proteomics model that lets us peer into what makes some patients click with Tyrosine...
Continue Reading
Top 5 Most Recently Viewed Articles
Fosun International Reports Impressive Interim Results Fosun International Limited (HKEX stock code: 00656, "Fosun International") has announced robust interim results, highlighting sustained growth across its core businesses. The total revenue reached RMB87.28 billion, with notable strides in global operations and technological innovation. Key Financial Highlights The...
Continue Reading
Flare Therapeutics Presents Groundbreaking Phase 1A Results Flare Therapeutics Inc. has recently made headlines with their announcement regarding the presentation of clinical data for FX-909, a promising therapeutic candidate in the fight against cancer. This upcoming presentation will take place at an esteemed conference focusing on molecular targets and cancer...
Continue Reading
RIV Capital Expands Adult-Use Cannabis Sales in Kingston RIV Capital Inc. (CSE: RIV) is making strides in the cannabis market with its recent announcement regarding the launch of adult-use sales at the Etain dispensary. This development marks a significant milestone in the company’s efforts to provide both medical and recreational cannabis to consumers. Location and...
Continue Reading
Water.org's Commitment to Addressing Water Issues Water.org is embarking on an ambitious journey in FY25, focusing on crucial strategies to tackle the world's water and sanitation crisis. Building on substantial accomplishments from FY24, the organization mobilized $965 million to provide safe water and sanitation to over 10.2 million people. Their relentless efforts to...
Continue Reading
Dexcom's Positive Revenue Outlook Shares of Dexcom (NASDAQ: DXCM), a leading company in medical devices focused on glucose monitoring systems, have experienced a notable uptick of 5%. This surge in stock value comes on the heels of their announcement regarding the anticipated revenue for 2025. Strong Fourth-Quarter Performance In an encouraging sign for investors,...
Continue Reading